Otilonium Bromide: Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄, MW 563.57) is a solid, high-purity (≥98%) antimuscarinic agent used to selectively inhibit acetylcholine receptors (AChRs) in both neuronal and smooth muscle cells (APExBIO). Its solubility profile enables versatile use in water (≥55.8 mg/mL), DMSO (≥28.18 mg/mL), and ethanol (≥91 mg/mL) at standard laboratory temperatures. Otilonium Bromide’s stability is maximized by storage at -20°C, with solutions recommended for short-term use only. The compound is widely adopted for elucidating cholinergic signaling pathways and modeling gastrointestinal motility disorders (related article). Usage is strictly limited to research applications, excluding diagnostic or clinical settings.

Biological Rationale

Cholinergic signaling underpins critical neural and smooth muscle functions, mediated primarily by acetylcholine and its receptor subtypes. Disruption or modulation of this pathway is central to modeling neurological and gastrointestinal conditions. Antimuscarinic agents like Otilonium Bromide allow for targeted inhibition of muscarinic acetylcholine receptors, providing mechanistic insights into receptor-specific physiology and pathology (Vijayan et al., 2021). Selective blockade of these receptors supports the development of models for smooth muscle spasm, neurotransmission, and motility disorders. The reliable performance and solubility profile of Otilonium Bromide facilitate its integration into diverse experimental workflows, including in vitro, ex vivo, and in vivo studies (contrast: extends solubility and application details).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide functions as a competitive antagonist at muscarinic acetylcholine receptors (mAChRs), particularly subtypes M2 and M3, which are predominant in smooth muscle and neuronal tissues. By occupying the orthosteric binding site, it prevents acetylcholine from activating downstream G-protein coupled signaling cascades, leading to reduced intracellular calcium mobilization and muscle contraction (APExBIO product page). This inhibition is reversible and dose-dependent, with effective concentrations determined by the tissue context and receptor density. The compound’s non-permeant, quaternary ammonium structure restricts blood-brain barrier permeability, enhancing selectivity for peripheral tissues. This property distinguishes Otilonium Bromide from tertiary amine antimuscarinics, minimizing CNS side effects in systemic models. In research, these features support its use in dissecting peripheral cholinergic mechanisms and studying smooth muscle physiology.

Evidence & Benchmarks

• Otilonium Bromide exhibits ≥98% purity as supplied by APExBIO, ensuring consistent experimental reproducibility (APExBIO).
• The compound displays water solubility of ≥55.8 mg/mL at room temperature, supporting high-concentration applications in aqueous buffers (APExBIO).
• Functional antagonism at M2 and M3 muscarinic receptors has been demonstrated in ex vivo smooth muscle models, resulting in inhibition of acetylcholine-induced contractions (see Table 1, Vijayan et al., 2021).
• Stability is maintained when stored as a solid at -20°C, with solutions remaining active for short-term periods under standard laboratory conditions (APExBIO).
• Benchmark studies use Otilonium Bromide for inducing pharmacological models of gastrointestinal motility disorders, enabling assessment of antispasmodic pharmacology (see Section 3.2, this article extends the competitive and translational context).

Applications, Limits & Misconceptions

Otilonium Bromide is leveraged in research protocols targeting the following domains:

• Neuroscience receptor modulation: Used to dissect muscarinic receptor roles in synaptic transmission and network activity.
• Smooth muscle spasm and motility disorder models: Applied to assess antispasmodic efficacy and receptor-specific contraction mechanisms (this article offers a forward-looking perspective on future directions).
• Cholinergic signaling pathway analysis: Enables controlled inhibition of AChRs for pathway mapping in neuronal and peripheral tissues.

Common Pitfalls or Misconceptions

• Not a CNS-penetrant agent: Due to its quaternary ammonium structure, Otilonium Bromide does not efficiently cross the blood-brain barrier; thus, it is unsuitable for direct central nervous system (CNS) receptor studies.
• Not for diagnostic or therapeutic use: This product is strictly for laboratory research; it is not approved for use in humans or animals as a drug (APExBIO).
• Decreased stability in solution: Solutions are intended for short-term use only; long-term storage can lead to degradation and loss of activity.
• Does not inhibit nicotinic receptors: Activity is selective for muscarinic, not nicotinic, acetylcholine receptors.
• Solubility context-dependent: Solubility values may vary with pH, temperature, and solvent purity; always verify under experimental conditions.

Workflow Integration & Parameters

For experimental use, Otilonium Bromide (B1607) from APExBIO can be dissolved in water, DMSO, or ethanol to prepare stock solutions at concentrations up to 91 mg/mL (in ethanol). For optimal results, stocks should be aliquoted and stored at -20°C, minimizing freeze-thaw cycles. Working solutions should be freshly prepared, filtered, and used within the same day to preserve antimuscarinic potency. Concentrations in functional assays typically range from 0.1 µM to 100 µM, adjusted according to tissue sensitivity and assay design. Researchers can reference the product documentation for detailed protocols and safety guidance. Compared to other antimuscarinic agents, Otilonium Bromide offers superior solubility and defined receptor selectivity, supporting its role as a reference inhibitor in smooth muscle and neuroscience research (this article contextualizes recent evidence and practical guidance).

Conclusion & Outlook

Otilonium Bromide, supplied by APExBIO, is a robust, high-purity antimuscarinic agent optimized for research on cholinergic signaling and smooth muscle spasm. Its defined mechanism, stability, and solubility profile enable precise experimental modulation of muscarinic receptor pathways. Future research will likely expand on its use in translational models of gastrointestinal and neurological disease, leveraging its selectivity and compatibility with modern assay platforms. For comprehensive application guidance and validated protocols, see the product page.